MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on developing and commercializing inhaled and other specialty therapies, with a commercial base in diabetes and cardiopulmonary care. Its portfolio includes Afrezza, an inhaled mealtime insulin, V-Go, a wearable insulin delivery device, and Furoscix, a subcutaneous furosemide therapy for fluid overload conditions, alongside collaboration and royalty revenue tied to partner products.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes Afrezza and V-Go, which are sold to support insulin therapy in diabetes care.
Includes Furoscix, used for outpatient treatment of fluid overload and heart-failure-related conditions.
Includes product sold to partners, contract manufacturing, and related service revenue.
Includes royalty income from partner commercial sales, especially Tyvaso DPI.
Products
Reported · share of revenue- Product Revenue61.8 %
- Royalty36.5 %
- Services1.2 %
- Manufacturing Services0.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
MannKind sells mainly through a limited set of wholesale distributors, specialty and retail pharmacies, durable medical suppliers, specialty distributors, and direct purchasers in the U.S. and India. Its end customers are patients and healthcare providers in diabetes and cardiopulmonary care, while collaboration revenue depends on commercial partners and their downstream sales performance.
Buy commercial products in bulk and resell into pharmacy and care channels; important for broad U.S. access.
Dispense Afrezza and related therapies to patients and help drive prescription fulfillment.
Purchase V-Go and similar products for distribution into diabetes care channels.
Buy directly in the U.S. and India, supporting localized commercial access.
Buy manufacturing, service, or product supply tied to partnered programs and royalty streams.
Strategy
MannKind is focused on expanding adoption of its approved products while maintaining the manufacturing and commercial infrastructure needed to support them. It is also reliant on collaboration economics, especially royalty and service revenue tied to Tyvaso DPI, so partner execution and partner product demand are central to its strategy.
Revenue depends on prescription uptake and channel access for Afrezza, V-Go and Furoscix.
Royalty and manufacturing income from UT is a meaningful revenue stream and depends on partner sales.
Commercial success depends on sufficient output and reliable sourcing of materials and components.
Geography
The company’s commercial revenue is concentrated in the United States, with additional direct customer activity in India and partner-related revenue tied to U.S. commercialization. Manufacturing and operations are centered in the U.S., including Danbury, Connecticut, which matters because supply continuity, regulatory compliance, and tariff exposure can affect product availability and cost.
Risks
The company faces commercialization risk because its products may achieve only limited market acceptance, particularly in competitive diabetes and heart-failure markets. It is also exposed to manufacturing, supplier, reimbursement, and partner-dependence risks, since revenue can be affected by production shortfalls, payer coverage, and strategic decisions made by collaborators such as United Therapeutics.
- Limited commercial success of approved productsImpact: HighLikelihood: Medium
Afrezza, V-Go and Furoscix compete against entrenched therapies and may not achieve broad uptake.
Exposure: Diabetes and heart-failure treatment markets
- Manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
The company must manufacture sufficient quantities and source materials reliably to support sales.
Exposure: Commercial product supply
- Payer coverage and reimbursement pressureImpact: HighLikelihood: Medium
If third-party payers do not cover products, prescriptions and sales can fall materially.
Exposure: U.S. commercial channels
- Partner concentration and dependence on United TherapeuticsImpact: HighLikelihood: Medium
Royalty and collaboration revenue depend on UT's sales and strategic priorities.
Exposure: Tyvaso DPI royalty stream
- Tariff and trade policy exposureImpact: MediumLikelihood: High
Higher import costs for raw materials and components could pressure gross margin.
Exposure: U.S. sourcing and manufacturing
Accounting
Judgemental itemsProduct sales are recorded net of discounts, rebates, chargebacks, returns and incentives.
Impact: Can materially affect reported revenue and receivables
Royalty income depends on partner net sales and contractual royalty terms.
Impact: Creates earnings sensitivity to partner sales trends
Service and product-supply arrangements may include deferred recognition and one-time items.
Impact: Can cause quarter-to-quarter revenue volatility
Valuation of acquired assets and contingent consideration requires estimates.
Impact: Can affect amortization and impairment charges
A meaningful non-cash expense for a development and commercial-stage biotech company.
Impact: Affects operating expense and reported profitability
Similar listed companies
Publicly listed companies with a comparable business focus.
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Cytokinetics, Incorporated
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Ironwood Pharmaceuticals, Inc
IRWD · Pharmaceutical Preparations
Ironwood Pharmaceuticals is a U.S.-based biopharmaceutical company focused on gastrointestinal therapies.
Last updated: 24/09/2026